cagrilintide semaglutide cagrisema phase 3 results 2024 2025 CAGRISEMA: The Latest Breakthrough in Weight-Loss Medication Novo Nordisk's next-gen obesity drug
Novo Nordisk's next gen obesity drug CagriSema trial results disappoint investors Novo Nordisk's CagriSema outperforms Ozempic in Phase III trial A stronger Ozempic is coming. What to know about CagriSema, Novo Nordisk's new weight loss drug Novo Nordisk's CagriSema 2.4 mg 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026
Pay in 4 interest-free payments of $5.39 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9



